Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2171182 | 0.84 | TSHR (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL17613683 | 0.82 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL17613650 | 0.82 | CA12 (0.34) | CA12CA1CA2CA9 | |
| SCHEMBL7940467 | 0.78 | — | — | |
| SCHEMBL12360854 | 0.77 | ALDH1A1 (0.38) | CA12CA1CA2CA9 | |
| SCHEMBL13425287 | 0.77 | CA12 (0.33) | CA12CA1CA2CA9 | |
| SCHEMBL13190642 | 0.75 | CA12 (0.32) | CA12CA1CA2CA9 | |
| SCHEMBL26636024 | 0.75 | CCNE2 (0.36) | CA12CA1CA2CA9 | |
| SCHEMBL15833396 | 0.74 | CA12 (0.41) | CA12CA1CA2CA9 | |
| SCHEMBL20610969 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | claimed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | claimed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | claimed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | claimed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | claimed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | claimed |
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | HOFFMANN-LA ROCHE INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN LA ROCHE (US) | 2021-01-21 | — | — | US | disclosed |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2019-05-16 | — | — | US | disclosed |
| EP-3442983-A1 | TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE | H. Hoffnabb-La Roche Ag (CH) | 2019-02-20 | — | — | EP | disclosed |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | HOFFMANN-LA ROCHE INC. | 2017-11-16 | — | — | US | disclosed |
| WO-2017178656-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2017-10-19 | — | — | WO | disclosed |
| EP-3204397-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. Hoffmann-La Roche AG (CH) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055601-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | F. HOFFMANN-LA ROCHE AG (CH) | 2016-04-14 | — | — | WO | disclosed |
| EP-2346883-B1 | SELF DELIVERING BIO-LABILE PHOSPHATE PROTECTED PRO-OLIGOS FOR OLIGONUCLEOTIDE BASED THERAPEUTICS AND MEDIATING RNA INTERFERENCE | PETERSEN SCOTT G (US) | 2016-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11248019-B2 | Trityl-mono-GalNAc compounds and their use | FUT6, GALNT1, FUT5 | CA12 576/4885CA1 1212/4885CA2 1698/4885 |
| US-20190144488-A1 | TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE | FUT6, GALNT1, FUT5 | CA12 576/4885CA1 1212/4885CA2 1698/4885 |
| US-20210017214-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | FUT6, FUT5, GALNT6 | CA12 761/4885CA1 2881/4885CA2 3321/4885 |
| US-20170327524-A1 | GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE | FUT6, FUT5, GALNT6 | CA12 761/4885CA1 2881/4885CA2 3321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.